Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 548,783	$ 147,914
Short-term investments	664,751	351,394
Receivable from collaboration partners ($29,262 and $744,535 from a related party)	29,419	744,595
Accrued interest receivable	2,746	2,227
Prepaid expenses and other current assets	18,527	15,620
Total current assets	1,264,226	1,261,750
Long-term investments	128,836	181,990
Property and equipment, net	33,481	32,455
Right-of-use assets	102,992	104,968
Restricted cash	3,005	3,005
Other long-term assets ($1,135 and $0 from a related party)	10,887	7,730
Total assets	1,543,427	1,591,898
Current liabilities:
Accounts payable	18,094	10,261
Accrued research and development	37,654	29,587
Other accrued liabilities	16,196	24,181
Deferred revenue, current ($87,018 and $96,981 to a related party)	89,310	102,003
Other current liabilities		52
Total current liabilities	161,254	166,084
Deferred revenue, noncurrent ($455,926 and $462,217 to a related party)	456,905	462,217
Operating lease liabilities, noncurrent	114,815	116,887
Other long-term liabilities	13,874	5,260
Total liabilities	746,848	750,448
Commitments (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 71,622,313 and 70,781,736 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. Shares outstanding includes zero and 9,946 shares issued but subject to vesting as of March 31, 2022 and December 31, 2021, respectively.	7	7
Additional paid-in capital	1,144,579	1,118,058
Accumulated deficit	(343,347)	(275,354)
Accumulated other comprehensive loss	(4,660)	(1,261)
Total stockholders’ equity	796,579	841,450
Total liabilities and stockholders’ equity	$ 1,543,427	$ 1,591,898